The two platforms involved in the study were the FHX regimen and a cisplatin radiation approach with accelerated radiation. Siltuximab was also used in the study as induction chemotherapy alongside carboplatin and paclitaxel.
Ezra Cohen, MD, professor of medicine, UC San Diego Moores Cancer Center, discusses a recent study looking at integrating siltuximab into two different chemotherapy radiation platforms. The two platforms involved in the study were the FHX regimen and a cisplatin radiation approach with accelerated radiation. Siltuximab was also used in the study as induction chemotherapy alongside carboplatin and paclitaxel. Cohen says patients were initially given the triplet, and then randomized to either the FHX regimen and a cisplatin radiation approach.
Need for Systemic Therapy Remains in Sarcoma
November 27th 2023In an interview with Targeted Oncology, Lisa B. Ercolano, MD, discussed the evolving treatment landscape for sarcomas and underscored the pivotal role of molecular profiling, while addressing the need for more efficacious systemic therapies.
Read More
BRUIN MCL-321 Trial Evaluates Pirtobrutinb Monotherapy in MCL
November 20th 2023In an interview with Targeted Oncology, Michael Wang, MD, discussed the rationale of the phase 3 study and how positive results from this trial may further shape the mantle cell lymphoma treatment landscape.
Read More
Neoadjuvant Pembro Plus Chemo Shows EFS Benefit at 5-Years in TNBC
November 13th 2023In an interview with Targeted Oncology, Peter Schmid, FRCP, MD, PhD, discussed the implication of findings from the KEYNOTE-522 trial of the addition of pembrolizumab to neoadjuvant chemotherapy in patients with high-risk triple-negative breast cancer.
Read More